Hørsholm,
The major contributors of value in the sum-of-the-parts valuation are ExpreS2ion's 34% stake in its joint venture with NextGen Vaccines, AdaptVac, ExpreS2ion's breast cancer vaccine candidate, ES2B-C001 HER2-cVLP, the company's Influenza program as part of the INDIGO consortium, and royalties from the PREVENT-nCoV COVID-19 vaccine program.
The full English version of the company-sponsored equity research report is attached to this press release.
Certified Adviser
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion
https://news.cision.com/expres2ion-biotechnologies/r/pareto-securities-as-initiates-equity-research-coverage-of-expres2ion-with-a-buy-rating-and-target-p,c3373906
https://mb.cision.com/Main/14402/3373906/1436663.pdf
https://mb.cision.com/Public/14402/3373906/823c8d97c030886e.pdf
https://news.cision.com/expres2ion-biotechnologies/i/proteinsforlife-blue-light,c2929434
(c) 2021 Cision. All rights reserved., source